Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-5857.88% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
AUPH · Mar 31, 2021
Aurinia Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-21-009306General Corporate
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
1743.54% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
94.75% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-5529.87% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1075.82% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
855.69% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History12 statesSelf-history eligible
Mar 31, 20210/6 normalizedLevel 3Jun 30, 20210/6 normalizedLevel 3Sep 30, 20210/6 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/7 normalizedLevel 3Dec 31, 20225/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Sep 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- -139.39%
- Current
- -5857.88%
- Delta
- -5718.49%
- Previous
- 27.79%
- Current
- 1743.54%
- Delta
- 1715.76%
- Previous
- -208.09%
- Current
- -5529.87%
- Delta
- -5321.78%
- Previous
- 100.42%
- Current
- 1075.82%
- Delta
- 975.40%
- Previous
- 34.83%
- Current
- 855.69%
- Delta
- 820.86%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · AUPH Fundamental State →Has State · Aurinia Pharmaceuticals Inc. →Transitioned To · AUPH CASH_GENERATION_DECREASED →Transitioned To · AUPH INVENTORY_PRESSURE_INCREASED →Transitioned To · AUPH PROFITABILITY_DECREASED →Transitioned To · AUPH R_AND_D_INTENSITY_INCREASED →Transitioned To · AUPH SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.